{
    "clinical_study": {
        "@rank": "144520", 
        "acronym": "ORVO", 
        "arm_group": [
            {
                "arm_group_label": "CRVO", 
                "arm_group_type": "Other", 
                "description": "Central Retinal Vein Occlusion"
            }, 
            {
                "arm_group_label": "BRVO", 
                "arm_group_type": "Other", 
                "description": "Branch Retinal Vein Occlusion"
            }
        ], 
        "brief_summary": {
            "textblock": "To measure the pro-permeability factors in the aqueous humor of patients with\n      persistent/recurrent macular edema after an injection of Ozurdex."
        }, 
        "brief_title": "Ozurdex for Retinal Vein Occlusion Study (ORVO Study)", 
        "condition": "Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "detailed_description": {
            "textblock": "To measure the pro-permeability factors VEGF, SDF-1, and angiopoietin-2 in the aqueous humor\n      of patients with persistent/recurrent macular edema despite prior treatment with anti-VEGF\n      agents at baseline and at 1, 2, 3, and 4 months after intraocular injection of OZURDEX."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent and authorization of use and disclosure of protected health\n             information\n\n          -  Age more than or equal to 18 years\n\n          -  Diagnosis of macular edema due to central or branch retinal vein occlusion\n\n          -  Intraretinal or subretinal fluid in the macula determined by Spectralis OCT\n\n          -  Best corrected visual acuity score in the study eye of 20/30 to 20/400 inclusive\n             (Snellen equivalents using the ETDRS protocol at a distance of 4 meters)\n\n          -  In the opinion of the investigator, decreased vision in the study eye is due to\n             foveal thickening from vein occlusion and not from other obvious causes of decreased\n             vision\n\n          -  Persistent or recurrent edema despite prolonged treatement with an anti-VEFG agent\n\n        Exclusion Criteria:\n\n          -  Scatter laser photocoagulation or macular photocoagulation within 3 months of study\n             entry in the study eye\n\n          -  Intraocular surgery in the study eye within 3 months of study entry\n\n          -  Use of intraocular or periocular injection of steroids in the study eye (e.g.,\n             triamcinolone) within 4 months of study entry\n\n          -  Previous use of an anti-VEGF drug within 1 month of study entry\n\n          -  Yttrium-Aluminum-Garnet (YAG) laser capsulotomy within 1 month of study entry\n\n          -  Any condition that the investigator believes would pose a significant hazard to the\n             subject if investigational therapy were initiated.\n\n          -  Inability to comply with study or follow up procedures\n\n          -  History of glaucoma or documented history of steroid-induced glaucoma.\n\n          -  Patients with active or suspected ocular or periocular infection, including most\n             viral diseases of the cornea and conjunctiva, including active epithelial herpes\n             simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial\n             infections, and fungal diseases.\n\n          -  Aphakic eyes with rupture of the posterior lens capsule.\n\n          -  Eyes with ACIOL and rupture of the posterior lens capsule.\n\n          -  Patients with hypersensitivity to dexamethasone or to any other components of the\n             product"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790685", 
            "org_study_id": "NA_00079951"
        }, 
        "intervention": {
            "arm_group_label": [
                "CRVO", 
                "BRVO"
            ], 
            "intervention_name": "dexamethasone implant", 
            "intervention_type": "Drug", 
            "other_name": "Ozurdex"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Baltimore", 
                    "country": "United States", 
                    "state": "Maryland", 
                    "zip": "21287"
                }, 
                "name": "Wilmer Eye Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Ozurdex for Retinal Vein Occlusion Study (ORVO Study)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome measure is a composite outcome that includes change from baseline in aqueous levels of VEGF, SDF-1, and angiopoietin-2 at 1, 2, 3, and 4 months after injection of OZURDEX.", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790685"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Peter A Campochiaro, MD", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Determine the percentage of patients with CRVO or BRVO with \u226515, \u226510, or \u22655 letters at 1, 2, 3, and 4 weeks after injection.\nDetermine the percentage of patients with reduction in excess foveal thickness by 50% or 90% at Weeks 24, and 48.\nAssess safety parameters including changes in intraocular pressure from baseline.", 
            "measure": "Measure Efficacy and safety parameters; these are composite outcomes", 
            "safety_issue": "Yes", 
            "time_frame": "4 months"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}